Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550414 | 1.00 | ADRB1 (0.39) | ADRB1MIFHTR2AADRA1AHTR2B | |
| SCHEMBL30137615 | 1.00 | ADRB1 (0.39) | ADRB1MIFHTR2AADRA1AHTR2B | |
| Hydrochloric Acid SCHEMBL2715092 | 0.98 | ALDH1A1 (0.39) | ADRB1MIFHTR2AADRA1AHTR2B | |
| Hydrochloric Acid SCHEMBL23247079 | 0.98 | ALDH1A1 (0.39) | ADRB1MIFHTR2AADRA1AHTR2B | |
| SCHEMBL659099 | 0.90 | ADRB2 (0.46) | ADRB1MIFHTR2AADRA1AHTR2B | |
| SCHEMBL27089977 | 0.87 | ADRB2 (0.39) | ADRB1MIFHTR2AADRA1AHTR2B | |
| SCHEMBL1538725 | 0.84 | PGK1 (0.48) | PGK1PGK2KDM4EALDH1A1NOTUM | |
| SCHEMBL14847092 | 0.83 | HDAC4 (0.47) | ADRB1MIFHTR2AADRA1AHTR2B | |
| SCHEMBL14975715 | 0.83 | HDAC4 (0.47) | ADRB1MIFHTR2AADRA1AHTR2B | |
| Hydrochloric Acid SCHEMBL14122255 | 0.81 | ALDH1A1 (0.45) | ADRB1MIFHTR2AADRA1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4600243-A2 | NOVEL BICYCLIC HETEROCYCLYL COMPOUNDS AND USE THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-05-15 | — | — | US | disclosed |
| EP-4463454-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2024-11-20 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | MEDSHINE DISCOVERY INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024075070-A2 | NOVEL BICYCLIC HETEROCYCLYL COMPOUNDS AND USE THEREOF | 제일약품주식회사 | 2024-04-11 | — | — | WO | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023135260-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023121413-A1 | NOVEL BICYCLIC HETEROCYCLYL COMPOUND AND USE THEREOF | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121413-A1 | NOVEL BICYCLIC HETEROCYCLYL COMPOUND AND USE THEREOF | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023109929-A1 | HETEROCYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-115611888-A | Pyridopyrimidinone derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | CYP3A7, UGT2B7, CYP51A1 | ADRB1 2702/4885MIF 4420/4885HTR2A 3367/4885 |
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | ADRB1 1661/4885MIF 3707/4885HTR2A 2741/4885 |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | ADRB1 687/4885MIF 3316/4885HTR2A 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.